According to a recent meta-analysis, the expression levels of PD-L1 were higher not only on tumor cells but also on immune cells in the TME in EBV-positive compared to EBV-negative cases of cHL, with risk ratios of 1.66 and 1.43, respectively [63]. This evidence concerns the gene CD274 and neoplasm.